What is Vaxxas?
Vaxxas is pioneering a proprietary high-density microarray patch (HD-MAP) for needle-free vaccine delivery. This innovative platform has demonstrated safety and efficacy in over 750 participants across multiple clinical trials, showing robust immune responses. The HD-MAP technology is versatile, capable of delivering various vaccine modalities, including live attenuated, protein subunit, and mRNA vaccines. By targeting immune cells directly beneath the skin, Vaxxas's approach aims to enhance protection with reduced vaccine doses, lower cold-chain requirements, and enable easier self-administration. This positions the company to significantly impact the global vaccine market by improving accessibility and reducing costs.
How much funding has Vaxxas raised?
Vaxxas has raised a total of $124.6M across 5 funding rounds:
Series A
$15M
Series B
$20M
Grant
$8.2M
Other Financing Round
$23M
Series D
$58.4M
Series A (2011): $15M, investors not publicly disclosed
Series B (2015): $20M led by Healthcare Ventures, Medical Research Commercialisation Fund (MRCF), Brandon Capital, and OneVentures
Grant (2022): $8.2M supported by Australian Government
Other Financing Round (2022): $23M featuring Uniquest and OneVentures
Series D (2025): $58.4M backed by Sprim Global Investments, OneVentures, Brandon Capital, and LGT Crestone Wealth Management
Key Investors in Vaxxas
Sprim Global Investments
Sprim Global Investments is a venture capital firm focused on enhancing R&D capabilities in the life sciences sector, investing in companies across biotech, medtech, and CROs. They support companies through various clinical stages with equity and debt investments.
OneVentures
OneVentures is an Australian venture capital firm that invests in technology and life science companies, providing capital and strategic support to help them scale and achieve market leadership.
Brandon Capital
Brandon Capital Partners is a venture capital firm specializing in seed and venture capital investments in the biomedical sector, focusing on life science companies with the potential to improve patient outcomes.
What's next for Vaxxas?
With its recent major strategic investment and a history of significant enterprise-level funding, Vaxxas is poised for commercialization. The company is scaling its manufacturing capabilities and advancing its lead programs. The successful clinical trial data and the platform's universal delivery potential suggest a strong trajectory toward market entry. Future developments will likely focus on regulatory approvals, broader clinical applications, and strategic partnerships to expand the reach of its needle-free vaccine delivery system globally.
See full Vaxxas company page
